Keyword: Hutchison China MediTech
Sanofi slims down in Japan. We examine Big Pharma CEOs' Chinese names. Positive data came out from Astellas, Eisai and Chi-Med at ESMO.
Indian drugmakers pick up U.S. generics scripts; Chi-Med files for Hong Kong listing; an explosion at a Qilu Pharma subsidiary kills 10.
Hutchison China MediTech’s Elunate, which was the first China-made drug to win a major oncology approval, has flopped in a key lung cancer trial.
Aurobindo buys parts of Sandoz for $1B; an ex-GSK scientist admits to stealing trade secrets; Lilly and Chi-Med's Chinese-made drug makes history.
China, which has been waving through cancer drugs made by multinational pharmas, can now count a homegrown one among its approvals.
Chinese pharmaceutical database PharmCube highlighted 16 possible blockbuster approvals in China in 2018.
AZ and Chi-Med scores early data for savolitinib combos in lung cancer, WuXi AppTec buys a U.S. CRO, FDA clears Sun's Dadra plant.
Nanjing Legend Biotech reported 100% ORR for a CAR-T product, Chi-Med touted fruquintinib's low liver toxicity, Eisai's Lenvima could challenge Bayer's Nexavar and more.
Novartis may face more furor in Korea, Astellas will develop a Prevnar rival with Affinivax, and Lilly and Chi-Med's colorectal cancer med aims for an NDA in China.